345 related articles for article (PubMed ID: 18182259)
21. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection.
Xu W; Shen Y; Jiang Z; Wang Y; Chu Y; Xiong S
Vaccine; 2004 Sep; 22(27-28):3603-12. PubMed ID: 15315839
[TBL] [Abstract][Full Text] [Related]
22. [Construction of recombinant house dust mite group 1 allergen vaccine and study on immune response induced by nasal immunization].
Shi WD; Cao W; Liu Y; Xu Y; Tao ZZ; Dai Q
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 Jan; 48(1):26-31. PubMed ID: 23656812
[TBL] [Abstract][Full Text] [Related]
23. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
[TBL] [Abstract][Full Text] [Related]
24. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes.
Shukla A; Katare OP; Singh B; Vyas SP
Int J Pharm; 2010 Jan; 385(1-2):47-52. PubMed ID: 19835938
[TBL] [Abstract][Full Text] [Related]
25. TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines.
Sayin B; Somavarapu S; Li XW; Sesardic D; Senel S; Alpar OH
Eur J Pharm Sci; 2009 Nov; 38(4):362-9. PubMed ID: 19733658
[TBL] [Abstract][Full Text] [Related]
26. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts.
Klavinskis LS; Barnfield C; Gao L; Parker S
J Immunol; 1999 Jan; 162(1):254-62. PubMed ID: 9886393
[TBL] [Abstract][Full Text] [Related]
27. Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response.
Pawar D; Jaganathan KS
Drug Deliv; 2016; 23(1):185-94. PubMed ID: 24825494
[TBL] [Abstract][Full Text] [Related]
28. Intranasal Administration of Novel Chitosan Nanoparticle/DNA Complexes Induces Antibody Response to Hepatitis B Surface Antigen in Mice.
Lebre F; Borchard G; Faneca H; Pedroso de Lima MC; Borges O
Mol Pharm; 2016 Feb; 13(2):472-82. PubMed ID: 26651533
[TBL] [Abstract][Full Text] [Related]
29. PEG-PLA-PEG block copolymeric nanoparticles for oral immunization against hepatitis B.
Jain AK; Goyal AK; Mishra N; Vaidya B; Mangal S; Vyas SP
Int J Pharm; 2010 Mar; 387(1-2):253-62. PubMed ID: 20005936
[TBL] [Abstract][Full Text] [Related]
30. Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems.
Singh J; Pandit S; Bramwell VW; Alpar HO
Methods; 2006 Feb; 38(2):96-105. PubMed ID: 16442811
[TBL] [Abstract][Full Text] [Related]
31. Chitosan nanoparticles encapsulated vesicular systems for oral immunization: preparation, in-vitro and in-vivo characterization.
Jain S; Sharma RK; Vyas SP
J Pharm Pharmacol; 2006 Mar; 58(3):303-10. PubMed ID: 16536896
[TBL] [Abstract][Full Text] [Related]
32. Oral delivery of microparticles containing plasmid DNA encoding hepatitis-B surface antigen.
Bhowmik T; D'Souza B; Uddin MN; D'Souza MJ
J Drug Target; 2012 May; 20(4):364-71. PubMed ID: 22339323
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.
Raghuwanshi D; Mishra V; Das D; Kaur K; Suresh MR
Mol Pharm; 2012 Apr; 9(4):946-56. PubMed ID: 22356166
[TBL] [Abstract][Full Text] [Related]
34. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Bento D; Staats HF; Gonçalves T; Borges O
Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
[TBL] [Abstract][Full Text] [Related]
35. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
Pawar D; Mangal S; Goswami R; Jaganathan KS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
[TBL] [Abstract][Full Text] [Related]
36. Strong cellular and humoral immune responses induced by transcutaneous immunization with HBsAg DNA-cationic deformable liposome complex.
Wang J; Hu JH; Li FQ; Liu GZ; Zhu QG; Liu JY; Ma HJ; Peng C; Si FG
Exp Dermatol; 2007 Sep; 16(9):724-9. PubMed ID: 17697144
[TBL] [Abstract][Full Text] [Related]
37. Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: results of an in vitro and in vivo study.
Zheng F; Shi XW; Yang GF; Gong LL; Yuan HY; Cui YJ; Wang Y; Du YM; Li Y
Life Sci; 2007 Jan; 80(4):388-96. PubMed ID: 17074366
[TBL] [Abstract][Full Text] [Related]
38. PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery.
Csaba N; Sánchez A; Alonso MJ
J Control Release; 2006 Jun; 113(2):164-72. PubMed ID: 16759732
[TBL] [Abstract][Full Text] [Related]
39. Low molecular weight chitosan in DNA vaccine delivery via mucosa.
Yang X; Yuan X; Cai D; Wang S; Zong L
Int J Pharm; 2009 Jun; 375(1-2):123-32. PubMed ID: 19481698
[TBL] [Abstract][Full Text] [Related]
40. Immunoglobulin immobilized liposomal constructs for transmucosal vaccination through nasal route.
Tiwari B; Agarwal A; Kharya AK; Lariya N; Saraogi G; Agrawal H; Agrawal GP
J Liposome Res; 2011 Sep; 21(3):181-93. PubMed ID: 20626315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
